Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients

A Phase I, Single Center, Randomized, Double-blind, Placebo Controlled, Single Dose (SD) and Multiple Dose (MD), Dose-escalation Clinical Trial to Evaluate the Tolerability and Preliminary Antiviral Activity of Therapeutic Hepatitis B Adenovirus Injection (T101) in Chronic Hepatitis B Patients

Hepatitis B virus (HBV) infection is a worldwide health problem. It has been proved that the persistence of HBV is associated with the failure to stimulate an efficient HBV-specific immune response. T101, the Chinese counterpart of TG1050, is a replication-defective adenovirus serotype 5 (Ad5) expressing multiple HBV-specific antigens (core, polymerase and envelope) and is used as therapeutic vaccine for chronic hepatitis B patients. The application of T101 aims at inducing a broad HBV-specific cellular immune response and ultimately eliminating HBV infection.

Study Overview

• Status: Completed
• Conditions: Hepatitis B Virus (HBV)
• Intervention / Treatment: Biological: T101 Group; Biological: Placebo Group

Detailed Description

This study is a randomized, double-blind, placebo-controlled, single dose (SD) and multiple dose (MD) administration study.

Primary Objective: Safety and tolerability;

Secondary Objective:

1. Antiviral activity of T101 (HBsAg levels).
2. Cellular (HBV-specific) and humoral (AD5 neutralizing antibodies, NAd5) immune responses to T101.

Key Inclusion Criteria:

1. Chronic hepatitis B patients with positive HBsAg.
2. Patients must be receiving antiviral treatment with nucleoside analogs and have negative HBV DNA (defined as HBV DNA <20 IU/mL).

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Changchun, China
    • The First Hospital of Jilin University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• 1) Signed, written Independent Ethics Committee (IEC)-approved informed consent.
• 2) Patients can cooperate to finish the trial in accordance with the requirements of protocol.
• 3）Patients (including partners) are willing to have no pregnancy program and take effective contraceptive measures voluntarily from the initiation of trial to 6 months after the last administration.
• 4) 18 through 65 years of age, inclusive.
• 5）Body weight is no less than 50 kg for male or no less than 45 kg for female and body mass index(BMI) must be within the range of 18-30kg/m2.
• 6）Compensated liver disease; defined as total bilirubin ≤2 × ULN, PT ≤ 1.2 ×ULN, platelets ≥100,000/mm3(100*109/L), serum albumin ≥35 g/L, and no prior history of clinical hepatic decompensation (eg, ascites, jaundice, encephalopathy, variceal hemorrhage).
• 7) Patients must be receiving antiviral treatment with nucleoside analog and have negative HBV DNA(defined HBV DNA <20 IU/Ml).
• 8) Chronic hepatitis B patients have positive HBsAg.
• 9) ALT ≤ 1.5×ULN.
• 10) Haemoglobin ≥ 10 g/L
• 11) Creatinine clearance > 50mL/min.
• 12) Neutrophils ≥1,200/mm3(1.2*109/L).
• 13) FibroScan score ≤ 17.5 kPa within 6 months prior to screening or during screening, or proven not to have cirrhosis according to liver tissues within 12 months.

Exclusion Criteria:

• 1) Addicted to smoking (>5 cigarettes per day) for 3 months prior to the initiation of trial.
• 2) Subjects susceptible to allergies, including a history of allergy to investigational medical product (IMP) or its buffer.
• 3) History of drug abuse and/or alcohol abuse(≥14 units of alcohol per week; 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine).
• 4) Patients who have donated or lost an amount of blood> 450ml within 3 months prior to the screening of the trial.
• 5) Patients who are positive urine test of drug on screening or a history of drug abuse or use of narcotic drugs during the past five years.
• 6) Patients who have used any drug that can alter the enzyme activity of liver within 28 days prior to screening.
• 7) Patients who have taken any prescription, nonprescription, vitamin product or herbal medicine within 14 days prior to the screening(except for nucleoside analogues).
• 8) Patients who have taken a special diet (including dragon fruit, mango, grapefruit, etc.) within 2 weeks prior to screening, or have strenuous exercise, or other factors that affect drug absorption, distribution, metabolism and excretion.
• 9) Patients who are taking inhibitors or inducers of CYP3A4, P-gp or Bcrp such as itraconazole, ketoconazole or dronedarone.
• 10) Patients who have significant changes in diet or exercise habit.
• 11) Patients who have participated in any clinical trial or taken any IMP within 3 months prior to the trial.
• 12) Patients with an clinically significant and abnormal ECG.
• 13) Female patients who are pregnant, breast-feeding or positive result of pregnancy test.
• 14) Patients with abnormal laboratory test results that have clinically significant or clinically significant disease(including but not limited to the gastrointestinal tract, kidney, liver, neurological, haematological, endocrine, lung, immune, mental or cardiovascular disease).
• 15) Patients with α-fetoprotein > 50 ng/Ml.
• 16) Patients with positive hepatitis C antibody, HIV antibody, or Treponema pallidum antibody on screening.
• 17) Patients who could not be enrolled in the judgement of the investigators.
• 18) Patients with acute disease or accompanied medication on screening.
• 19) Patients who have taken chocolate or any food and drink that are rich in caffeine or xanthine within 48 hours prior to the administration of IMP.
• 20) Patients who have taken any alcohol product within 24 hours prior to the administration of IMP.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: T101 Group; The study will consist of 2 cohorts: Single Dose (SD) Cohort: 9 chronic hepatitis B patients will be enrolled and be divided into 3 groups, with 3 patients in each group. Multiple Dose (MD) Cohort: 18 chronic hepatitis B patients will be enrolled and be divided into 2 groups, with 9 patients in each group.	Biological: T101 Group; Single Dose (SD) Cohort: In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1. Multiple Dose (MD) Cohort: In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15.
PLACEBO_COMPARATOR: Placebo Group; The study will consist of 2 cohorts: Single Dose (SD) Cohort: 3 chronic hepatitis B patients will be enrolled in this group. Multiple Dose (MD) Cohort: 6 chronic hepatitis B patients will be enrolled in this group.	Biological: Placebo Group; Single Dose (SD) Cohort: 3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1. Multiple Dose (MD) Cohort: 6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events	Observe all the adverse events of all patients, record their clinical features, severity, time of occurence, end time, duration, treatment measures, recovery and determine their correlation with T101	through study completion, an average of 1 year
Vital signs index	vital signs measure: include body temperature, pulse rate, respiratory rate and blood pressure, to observe whether there are abnormal index, especially whether there are abnormal index caused by acute allergic reaction.	Single Dose Group: baseline, Day-1, Day1, Day8, Day15, Day2ine9; Multiple Dose Group: baseline, Day-1, Day7, Day8, Day14, Day15, Day22, Day29, Day43, Day71, Day99.
Routine blood test	Observe the blood routine tests results of all patients, compare the change of each index before and after the treatment, and determine their correlation with T101 if abnormal index occur.	Single Dose Group: baseline, Day-1, Day8, Day15, Day29; Multiple Dose Group: baseline, Day-1, Day7, Day14, Day22, Day29, Day43, Day71, Day99, Day 197, Day379.
Blood biochemical test	Observe the blood biochemical tests results of all patients, compare the change of each index before and after the treatment, and determine their correlation with T101 if abnormal index occur.	Single Dose Group: baseline, Day-1, Day8, Day15, Day29; Multiple Dose Group: baseline, Day-1, Day7, Day14, Day22, Day29, Day43, Day71, Day99, Day 197, Day379.
Coagulation function test	Observe the coagulation function tests results of all patients, compare the change of each index before and after the treatment, and determine their correlation with T101 if abnormal index occur.	Single Dose Group: baseline, Day-1, Day8, Day15, Day29; Multiple Dose Group: baseline, Day-1, Day7, Day14, Day22, Day29, Day43, Day71, Day99, Day 197, Day379.
Routine urinalysis	Observe the routine urinalysis tests results of all patients, compare the change of each index before and after the treatment, and determine their correlation with T101 if abnormal index occur.	Single Dose Group: baseline, Day-1, Day8, Day15, Day29; Multiple Dose Group: baseline, Day-1, Day7, Day14, Day22, Day29, Day43, Day71, Day99, Day 197, Day379.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
HBsAg quantitative levels	Evaluate the efficacy of T101	Single Dose Group: Day1, Day29; Multiple Dose Group: Day1, Day29, Day43, Day71, Day99, Day197, Day379.
HBeAg quantitative levels	Evaluate the efficacy of T101	Single Dose Group: Day1, Day29; Multiple Dose Group: Day1, Day29, Day43, Day71, Day99, Day197, Day379.
Ad5 neutralizing antibodies	Use Analysis of luciferase Ad5 neutralizing antibody method to evaluate the changes of NAd5 titers after T101 administration	Single Dose Group: Day1, Day15, Day29; Multiple Dose Group: Day1, Day29, Day43, Day71, Day99, Day197, Day379.
Cellular and humoral immune responses	Detect the T-cell responses by interferon-γ（INF-γ） ELISPOT	Single Dose Group: Day1, Day15, Day29; Multiple Dose Group: Day1, Day29, Day43, Day71, Day99, Day197, Day379.

Collaborators and Investigators

• Sponsor: Tasly Tianjin Biopharmaceutical Co., Ltd.

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 8, 2018
• Primary Completion (ACTUAL): October 14, 2019
• Study Completion (ACTUAL): October 14, 2019

Study Registration Dates

• First Submitted: October 24, 2019
• First Submitted That Met QC Criteria: November 15, 2019
• First Posted (ACTUAL): November 19, 2019

Study Record Updates

• Last Update Posted (ACTUAL): December 4, 2019
• Last Update Submitted That Met QC Criteria: December 2, 2019
• Last Verified: December 1, 2019

More Information

Terms related to this study

• Keywords: Hepatitis B virus (HBV) infection
• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Hepatitis B; Hepatitis; Hepatitis A; Hepatitis B, Chronic
• Other Study ID Numbers: TC-2017-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No